<!DOCTYPE html>
<!-- Generated by pkgdown: do not edit by hand --><html lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"><meta charset="utf-8"><meta http-equiv="X-UA-Compatible" content="IE=edge"><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"><meta name="description" content="Background
The example simulated data set is based on large phase III clinical trials in
breast cancer such as the ALTTO trial doi:10.1200/JCO.2015.62.1797
.
The example trial aims to determine if a combination of two therapies
tablemab (T) plus vismab (V) improves outcomes for metastatic human epidermal
growth factor 2-positive breast cancer and increases the pathologic complete
response in the neoadjuvant setting (i.e. treatment given as a first step to
shrink a tumor before the main treatment or surgery).
The trial has four treatment arms, patients with centrally confirmed human
epidermal growth factor 2-positive early breast cancer were randomly assigned
to 1 year of adjuvant therapy with V, T, their sequence (T to V), or their
combination (T+V) for 52 weeks.
The primary end point was progression-free survival (PFS) as defined by
Cancer.gov: '&quot;the length of time during and after the treatment of a disease,
such as cancer, that a patient lives with the disease but it does not get
worse. In a clinical trial, measuring the progression-free survival is one
way to see how well a new treatment works&quot;'.
A number of baseline measurements (taken at randomization) are also included
such as age, hormone receptor status and prior radiotherapy treatment.
Additional details on reasons for study discontinuation and censoring
event description are also included.
The data set adopts an abridged version of the CDISC ADaM ADTTE
time to event data model. See here for more info on CDISC ADaM data standards
https://www.cdisc.org/standards/foundational/adam and specifically the
ADTTE time to event data model here
https://www.cdisc.org/standards/foundational/adam/adam-basic-data-structure-bds-time-event-tte-analyses-v1-0."><title>Formatted Copy of ggsurvfit::adtte — easy_adtte • easysurv</title><!-- favicons --><link rel="icon" type="image/png" sizes="16x16" href="../favicon-16x16.png"><link rel="icon" type="image/png" sizes="32x32" href="../favicon-32x32.png"><link rel="apple-touch-icon" type="image/png" sizes="180x180" href="../apple-touch-icon.png"><link rel="apple-touch-icon" type="image/png" sizes="120x120" href="../apple-touch-icon-120x120.png"><link rel="apple-touch-icon" type="image/png" sizes="76x76" href="../apple-touch-icon-76x76.png"><link rel="apple-touch-icon" type="image/png" sizes="60x60" href="../apple-touch-icon-60x60.png"><script src="../deps/jquery-3.6.0/jquery-3.6.0.min.js"></script><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"><link href="../deps/bootstrap-5.3.1/bootstrap.min.css" rel="stylesheet"><script src="../deps/bootstrap-5.3.1/bootstrap.bundle.min.js"></script><!-- Font Awesome icons --><link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.12.1/css/all.min.css" integrity="sha256-mmgLkCYLUQbXn0B1SRqzHar6dCnv9oZFPEC1g1cwlkk=" crossorigin="anonymous"><link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.12.1/css/v4-shims.min.css" integrity="sha256-wZjR52fzng1pJHwx4aV2AO3yyTOXrcDW7jBpJtTwVxw=" crossorigin="anonymous"><!-- bootstrap-toc --><script src="https://cdn.jsdelivr.net/gh/afeld/bootstrap-toc@v1.0.1/dist/bootstrap-toc.min.js" integrity="sha256-4veVQbu7//Lk5TSmc7YV48MxtMy98e26cf5MrgZYnwo=" crossorigin="anonymous"></script><!-- headroom.js --><script src="https://cdnjs.cloudflare.com/ajax/libs/headroom/0.11.0/headroom.min.js" integrity="sha256-AsUX4SJE1+yuDu5+mAVzJbuYNPHj/WroHuZ8Ir/CkE0=" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/headroom/0.11.0/jQuery.headroom.min.js" integrity="sha256-ZX/yNShbjqsohH1k95liqY9Gd8uOiE1S4vZc+9KQ1K4=" crossorigin="anonymous"></script><!-- clipboard.js --><script src="https://cdnjs.cloudflare.com/ajax/libs/clipboard.js/2.0.11/clipboard.min.js" integrity="sha512-7O5pXpc0oCRrxk8RUfDYFgn0nO1t+jLuIOQdOMRp4APB7uZ4vSjspzp5y6YDtDs4VzUSTbWzBFZ/LKJhnyFOKw==" crossorigin="anonymous" referrerpolicy="no-referrer"></script><!-- search --><script src="https://cdnjs.cloudflare.com/ajax/libs/fuse.js/6.4.6/fuse.js" integrity="sha512-zv6Ywkjyktsohkbp9bb45V6tEMoWhzFzXis+LrMehmJZZSys19Yxf1dopHx7WzIKxr5tK2dVcYmaCk2uqdjF4A==" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/autocomplete.js/0.38.0/autocomplete.jquery.min.js" integrity="sha512-GU9ayf+66Xx2TmpxqJpliWbT5PiGYxpaG8rfnBEk1LL8l1KGkRShhngwdXK1UgqhAzWpZHSiYPc09/NwDQIGyg==" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/mark.js/8.11.1/mark.min.js" integrity="sha512-5CYOlHXGh6QpOFA/TeTylKLWfB3ftPsde7AnmhuitiTX4K5SqCLBeKro6sPS8ilsz1Q4NRx3v8Ko2IBiszzdww==" crossorigin="anonymous"></script><!-- pkgdown --><script src="../pkgdown.js"></script><link href="../extra.css" rel="stylesheet"><meta property="og:title" content="Formatted Copy of ggsurvfit::adtte — easy_adtte"><meta property="og:description" content="Background
The example simulated data set is based on large phase III clinical trials in
breast cancer such as the ALTTO trial doi:10.1200/JCO.2015.62.1797
.
The example trial aims to determine if a combination of two therapies
tablemab (T) plus vismab (V) improves outcomes for metastatic human epidermal
growth factor 2-positive breast cancer and increases the pathologic complete
response in the neoadjuvant setting (i.e. treatment given as a first step to
shrink a tumor before the main treatment or surgery).
The trial has four treatment arms, patients with centrally confirmed human
epidermal growth factor 2-positive early breast cancer were randomly assigned
to 1 year of adjuvant therapy with V, T, their sequence (T to V), or their
combination (T+V) for 52 weeks.
The primary end point was progression-free survival (PFS) as defined by
Cancer.gov: '&quot;the length of time during and after the treatment of a disease,
such as cancer, that a patient lives with the disease but it does not get
worse. In a clinical trial, measuring the progression-free survival is one
way to see how well a new treatment works&quot;'.
A number of baseline measurements (taken at randomization) are also included
such as age, hormone receptor status and prior radiotherapy treatment.
Additional details on reasons for study discontinuation and censoring
event description are also included.
The data set adopts an abridged version of the CDISC ADaM ADTTE
time to event data model. See here for more info on CDISC ADaM data standards
https://www.cdisc.org/standards/foundational/adam and specifically the
ADTTE time to event data model here
https://www.cdisc.org/standards/foundational/adam/adam-basic-data-structure-bds-time-event-tte-analyses-v1-0."><meta property="og:image" content="https://maple-health-group.github.io/easysurv/logo.png"><!-- mathjax --><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/MathJax.js" integrity="sha256-nvJJv9wWKEm88qvoQl9ekL2J+k/RWIsaSScxxlsrv8k=" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/config/TeX-AMS-MML_HTMLorMML.js" integrity="sha256-84DKXVJXs0/F8OTMzX4UR909+jtl4G7SPypPavF+GfA=" crossorigin="anonymous"></script><!--[if lt IE 9]>
<script src="https://oss.maxcdn.com/html5shiv/3.7.3/html5shiv.min.js"></script>
<script src="https://oss.maxcdn.com/respond/1.4.2/respond.min.js"></script>
<![endif]--></head><body>
    <a href="#main" class="visually-hidden-focusable">Skip to contents</a>
    

    <nav class="navbar fixed-top navbar-dark navbar-expand-lg bg-primary" data-bs-theme="dark"><div class="container">
    
    <a class="navbar-brand me-2" href="../index.html">easysurv</a>

    <small class="nav-text text-muted me-auto" data-bs-toggle="tooltip" data-bs-placement="bottom" title="">2.0.1</small>

    
    <button class="navbar-toggler" type="button" data-bs-toggle="collapse" data-bs-target="#navbar" aria-controls="navbar" aria-expanded="false" aria-label="Toggle navigation">
      <span class="navbar-toggler-icon"></span>
    </button>

    <div id="navbar" class="collapse navbar-collapse ms-3">
      <ul class="navbar-nav me-auto"><li class="nav-item">
  <a class="nav-link" href="../articles/easysurv.html">Get started</a>
</li>
<li class="active nav-item">
  <a class="nav-link" href="../reference/index.html">Reference</a>
</li>
<li class="nav-item">
  <a class="nav-link" href="../news/index.html">Changelog</a>
</li>
      </ul><form class="form-inline my-2 my-lg-0" role="search">
        <input type="search" class="form-control me-sm-2" aria-label="Toggle navigation" name="search-input" data-search-index="../search.json" id="search-input" placeholder="Search for" autocomplete="off"></form>

      <ul class="navbar-nav"><li class="nav-item">
  <a class="external-link nav-link" href="https://github.com/Maple-Health-Group/easysurv/" aria-label="github">
    <span class="fab fa fab fa-github fa-lg"></span>
     
  </a>
</li>
      </ul></div>

    
  </div>
</nav><div class="container template-reference-topic">
<div class="row">
  <main id="main" class="col-md-9"><div class="page-header">
      <img src="../logo.png" class="logo" alt=""><h1>Formatted Copy of <a href="http://www.danieldsjoberg.com/ggsurvfit/reference/adtte.html" class="external-link">ggsurvfit::adtte</a></h1>
      <small class="dont-index">Source: <a href="https://github.com/Maple-Health-Group/easysurv/blob/HEAD/R/data.R" class="external-link"><code>R/data.R</code></a></small>
      <div class="d-none name"><code>easy_adtte.Rd</code></div>
    </div>

    <div class="ref-description section level2">
    <p>Background
The example simulated data set is based on large phase III clinical trials in
breast cancer such as the ALTTO trial <a href="https://doi.org/10.1200/JCO.2015.62.1797" class="external-link">doi:10.1200/JCO.2015.62.1797</a>
.
The example trial aims to determine if a combination of two therapies
tablemab (T) plus vismab (V) improves outcomes for metastatic human epidermal
growth factor 2-positive breast cancer and increases the pathologic complete
response in the neoadjuvant setting (i.e. treatment given as a first step to
shrink a tumor before the main treatment or surgery).</p>
<p>The trial has four treatment arms, patients with centrally confirmed human
epidermal growth factor 2-positive early breast cancer were randomly assigned
to 1 year of adjuvant therapy with V, T, their sequence (T to V), or their
combination (T+V) for 52 weeks.</p>
<p>The primary end point was progression-free survival (PFS) as defined by
Cancer.gov: '"the length of time during and after the treatment of a disease,
such as cancer, that a patient lives with the disease but it does not get
worse. In a clinical trial, measuring the progression-free survival is one
way to see how well a new treatment works"'.</p>
<p>A number of baseline measurements (taken at randomization) are also included
such as age, hormone receptor status and prior radiotherapy treatment.</p>
<p>Additional details on reasons for study discontinuation and censoring
event description are also included.</p>
<p>The data set adopts an abridged version of the CDISC ADaM ADTTE
time to event data model. See here for more info on CDISC ADaM data standards
<a href="https://www.cdisc.org/standards/foundational/adam" class="external-link">https://www.cdisc.org/standards/foundational/adam</a> and specifically the
ADTTE time to event data model here
<a href="https://www.cdisc.org/standards/foundational/adam/adam-basic-data-structure-bds-time-event-tte-analyses-v1-0" class="external-link">https://www.cdisc.org/standards/foundational/adam/adam-basic-data-structure-bds-time-event-tte-analyses-v1-0</a>.</p>
    </div>

    <div class="section level2">
    <h2 id="ref-usage">Usage<a class="anchor" aria-label="anchor" href="#ref-usage"></a></h2>
    <div class="sourceCode"><pre class="sourceCode r"><code><span><span class="va">easy_adtte</span></span></code></pre></div>
    </div>

    <div class="section level2">
    <h2 id="format">Format<a class="anchor" aria-label="anchor" href="#format"></a></h2>
    <p>The data set contains the following variables:</p>
<dl><dt>STUDYID</dt>
<dd><p>The study identifier. A code unique to the clinical trial</p></dd>

<dt>SUBJID</dt>
<dd><p>subject identifier. Numeric ID unique to each patient</p></dd>

<dt>USUBJID</dt>
<dd><p>unique subject identifier. Text ID combining study and patient IDs</p></dd>

<dt>AGE</dt>
<dd><p>age at randomisation (years)</p></dd>

<dt>STR01</dt>
<dd><p>Hormone receptor status at randomisation</p></dd>

<dt>STR01N</dt>
<dd><p>Hormone receptor positive (Numeric)</p></dd>

<dt>STR01L</dt>
<dd><p>Hormone receptor positive (Long format)</p></dd>

<dt>STR02</dt>
<dd><p>Prior Radiotherapy at randomisation</p></dd>

<dt>STR02N</dt>
<dd><p>Prior Radiotherapy at randomisation (Numeric)</p></dd>

<dt>STR02L</dt>
<dd><p>Prior Radiotherapy at randomisation (Long format)</p></dd>

<dt>TRT01P</dt>
<dd><p>Planned treatment assigned at randomisation</p></dd>

<dt>TRT01PN</dt>
<dd><p>Planned treatment assigned at randomisation (Numeric)</p></dd>

<dt>PARAM</dt>
<dd><p>Analysis parameter: Progression free survival</p></dd>

<dt>PARAMCD</dt>
<dd><p>Analysis parameter code</p></dd>

<dt>AVAL</dt>
<dd><p>Analysis value (time to event (years)</p></dd>

<dt>CNSR</dt>
<dd><p>Censoring (0 = Event, 1 = Censored)</p></dd>

<dt>EVNTDESC</dt>
<dd><p>Event description</p></dd>

<dt>CNSDTDSC</dt>
<dd><p>Censoring description</p></dd>

<dt>DCTREAS</dt>
<dd><p>Discontinuation from study reason</p></dd>


</dl></div>
    <div class="section level2">
    <h2 id="source">Source<a class="anchor" aria-label="anchor" href="#source"></a></h2>
    <p><a href="http://www.danieldsjoberg.com/ggsurvfit/reference/adtte.html" class="external-link">ggsurvfit::adtte</a></p>
    </div>

  </main><aside class="col-md-3"><nav id="toc"><h2>On this page</h2>
    </nav></aside></div>


    <footer><div class="pkgdown-footer-left">
  <p>Developed by Niall Davison, Brad Kievit, Maple Health Group, LLC.</p>
</div>

<div class="pkgdown-footer-right">
  <p>Site built with <a href="https://pkgdown.r-lib.org/" class="external-link">pkgdown</a> 2.0.9.</p>
</div>

    </footer></div>

  

  

  </body></html>

